J Korean Diabetes.  2023 Mar;24(1):12-17. 10.4093/jkd.2023.24.1.12.

Diabetes and Cancer

• Hong JW

• KMID: 2540915
• DOI: http://doi.org/10.4093/jkd.2023.24.1.12

Abstract

Diabetes mellitus and cancer are the most common life-threatening illnesses worldwide. Previous epidemiologic studies have suggested a strong association between increased risk of cancer and diabetes mellitus. Potential biological mechanisms underlying the relationship include obesity, hyperglycemia, hyperinsulinemia, chronic inflammation, and oxidative stress. The most common diabetes-related cancers are pancreatic cancer, hepatocellular cancer, breast cancer, endometrial cancer, and colorectal cancer. Special attention should be paid to diabetic patients using careful cancer screening and providing preventive anti-cancer strategies.

Keyword

Cancer; Diabetes mellitus; Screening

Reference

1.Wojciechowska J., Krajewski W., Bolanowski M., Kręcicki T., Zatoński T. Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016. 124:263–75.

2.Carstensen B., Read SH., Friis S., Sund R., Keskimäki I., Svensson AM., Diabetes and Cancer Research Consortium, et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia. 2016. 59:980–8.

3.Larsson SC., Orsini N., Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005. 97:1679–87.

4.Kim YJ., Oh CM., Park SK., Jung JY., Kim MH., Ha E, et al. Fasting blood glucose and risk of incident pancreatic cancer. PLoS One. 2022. 17:e0274195.

5.Davila JA., Morgan RO., Shaib Y., McGlynn KA., El-Serag HB. Diabetes increases the risk of hepatocellular carcino-ma in the United States: a population based case control study. Gut. 2005. 54:533–9.

6.Vona-Davis L., Howard-McNatt M., Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007. 8:395–408.

7.Friberg E., Orsini N., Mantzoros CS., Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007. 50:1365–74.

8.Gong Z., Neuhouser ML., Goodman PJ., Albanes D., Chi C., Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006. 15:1977–83.

9.Kang YM., Kim YJ., Park JY., Lee WJ., Jung CH. Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013. Cardiovasc Diabetol. 2016. 15:131.

10.Giovannucci E., Harlan DM., Archer MC., Bergenstal RM., Gapstur SM., Habel LA, et al. Diabetes and cancer: a con-sensus report. Diabetes Care. 2010. 33:1674–85.

11.International Agency for Research on Cancer (IARC). IARC handbooks of cancer prevention volume 6. Weight control and physical activity. Lyon: IARC;2002.

12.World Cancer Research Fund; American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. 2nd ed.Washington, D.C.: American Institute for Cancer Research;2007.

13.Ryu TY., Park J., Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J. 2014. 38:330–6.

14.Noto H., Goto A., Tsujimoto T., Osame K., Noda M. Latest insights into the risk of cancer in diabetes. J Diabetes In-vestig. 2013. 4:225–32.

15.van Kruijsdijk RC., van der Wall E., Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009. 18:2569–78.

16.American Diabetes Association. 4. Comprehensive medi-cal evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019. 42(Suppl 1):S34–45.

17.Chuck KW., Hwang M., Choi KS., Suh M., Jun JK., Park B. Cancer screening rate in people with diabetes in the Korean population: results from the Korea National Health and Nutrition Examination Survey 2007-2009. Epidemiol Health. 2017. 39:e2017036.

18.Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009. 52:1755–65. Erratum in: Diabetologia. 2009. 52:2469

19.Jonasson JM., Ljung R., Talbäck M., Haglund B., Gudbjörns-dòttir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009. 52:1745–54.

20.ORIGIN Trial Investigators., Gerstein HC., Bosch J., Dage-nais GR., Díaz R., Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012. 367:319–28.

21.Libby G., Donnelly LA., Donnan PT., Alessi DR., Morris AD., Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009. 32:1620–5.

22.Jiralerspong S., Palla SL., Giordano SH., Meric-Bernstam F., Liedtke C., Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009. 27:3297–302.

23.Decensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010. 3:1451–61.

24.Libby G., Donnelly LA., Donnan PT., Alessi DR., Morris AD., Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009. 32:1620–5.

25.Dormandy JA., Charbonnel B., Eckland DJ., Erdmann E., Massi-Benedetti M., Moules IK., PROactive Investigators, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascu-lar Events): a randomised controlled trial. Lancet. 2005. 366:1279–89.

26.Mehtälä J., Khanfir H., Bennett D., Ye Y., Korhonen P., Hoti F. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int. 2018. 10:24–36.

27.Zhang Z., Chen X., Lu P., Zhang J., Xu Y., He W, et al. Incre-tin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017. 16:31.

28.Tang H., Dai Q., Shi W., Zhai S., Song Y., Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017. 60:1862–72.